/Passle/5e8c58ad3dccd208784b45a3/MediaLibrary/Images/2024-10-15-19-53-27-360-670ec837dd71ccaa0996a993.png)
Significant Chinese investment in its biotechnology industry has resulted in a shift in the biopharma licensing market over the last five...
The BIOSECURE Act, first introduced in Congress last year, has now been reintroduced for inclusion in Senate’s draft of the annual...
As big pharmas and other commercial-stage biopharma and biotech companies grapple with the reality of patent cliffs on the horizon, which...
We asked more than 200 Freshfields lawyers – across geographies and practice areas: what are the 1-2 issues top of mind for you and your...
/Passle/5e8c58ad3dccd208784b45a3/MediaLibrary/Images/5e7cb459342a4f03803cef70/2021-02-05-19-53-09-725-601da2255354890560beaf3e.jpg)
According to settled Supreme Court case law, the holder of a patent may not require a licensee to pay royalties after the patent...
/Passle/5e8c58ad3dccd208784b45a3/MediaLibrary/Images/5e7cb459342a4f03803cef70/2020-11-19-17-28-20-832-5fb6ab34e5416a0eb07cb3a6.png)
On June 18, 2024, the Federal Trade Commission (FTC) issued a comment (the FTC Comment) responding to the United States Patent and...
On May 22, 2024, the U.S. National Institutes of Health (NIH) announced it was soliciting feedback on a proposed policy (the Policy)1...
/Passle/5e8c58ad3dccd208784b45a3/MediaLibrary/Images/5dad74218cb623000828a1ec/2021-01-21-15-57-44-299-6009a478e5416a0a5c2838e8.jpg)
The Bayh-Dole Act of 1980 provides certain rights in favor of the U.S. government in order to ensure that products arising from federally...
The recent surge in bolt-on M&A in the life sciences sector is being fueled by the use of contingent value rights. Notwithstanding...
The 21st annual Biomed Israel Conference, attended by thousands of industry leaders from 45 countries, presented a juxtaposition of...
In the past few months, proposals from the United States Patent and Trademark Office (“USPTO”) have drawn the attention of organizations,...
The Association of Corporate Counsel hosted its annual Life Sciences Conference from May 9-11, 2023, which featured presentations from a...
In our January blog post on this topic, The Drug Pricing Landscape in 2023: Renewed Pressure for Pricing Reform, we speculated that in...
Acquisitions of public companies in pharma, biotech, and other life sciences industries are increasingly using deal structures designed...
This isn’t the first time we’ve written about this US-focused transaction in the innovative markets for next generation gene sequencing...
This article originally appeared in Life Science Leader on July 1, 2022. As has now become an annual tradition, when the calendar turned...